Neugenesis Corporation Unveils New Technology For Rapid Production Of Influenza Vaccines
10/19/2005 5:11:57 PM
Neugenesis Corporation today announced the discovery of a method for producing vaccines for influenza and other diseases which radically improves upon current processes. The Neugenesis technology dramatically shortens production time for vaccines, improves sterility in the growth environment, is significantly less expensive and eliminates egg-based allergic reactions. Using the rapid Neugenesis method, vaccine production can occur in as little as 6 weeks in a sterile lab environment, eliminating the traditional reliance upon animal products. The rapid development capability of the Neugenesis technology gives vaccine producers greater flexibility in developing vaccines like the influenza vaccine, where the disease strain may change rapidly. It further minimizes the risk of contamination and offers a new option for those with egg allergies.
comments powered by